These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 5389014)

  • 21. [Therapy of leprosy].
    Ilardi I; Mazzacurati G
    Clin Ter; 1969 Feb; 48(3):265-88. PubMed ID: 4929555
    [No Abstract]   [Full Text] [Related]  

  • 22. Relapse rates in patients treated with dapsone monotherapy and combinations of dapsone and thiambutosine, thiacetazone, isoniazid and streptomycin in the pre-MDT era.
    Smith TC; Richardus JH
    Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):353-8. PubMed ID: 7525795
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of dapsone on blood lactic and pyruvic acids in leprosy.
    Sinha SN; Gupta SC; Bajaj AK; Srivastava NP; Mehrotra TN
    Int J Lepr Other Mycobact Dis; 1982 Dec; 50(4):468-70. PubMed ID: 6892022
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of the treatment of 15 cases of lepromatous leprosy with 4-4'-diaminodiphenylsulfone].
    LANGUILLON J
    Bull Soc Pathol Exot Filiales; 1951; 44(5-6):322-9. PubMed ID: 13066934
    [No Abstract]   [Full Text] [Related]  

  • 26. Relapses in leprosy patients treated with rifampicin plus dapsone after varying periods of dapsone monotherapy.
    Li HY; Ran SP; Weng XM; Li TG; Deng XH; Li FT
    Indian J Lepr; 2001; 73(1):1-10. PubMed ID: 11326592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunostimulation with an allied mycobacterium and DDS chemotherapy in lepromatous leprosy.
    Chaudhury S; Hazra S; Chatterjee BC; Dey SK; Chaudhury SN; Das P
    Indian J Dermatol; 1985 Oct; 30(4):3-10. PubMed ID: 3843558
    [No Abstract]   [Full Text] [Related]  

  • 28. A century of progress in the therapy of leprosy.
    Karat AB; Ramanujam K
    Int J Lepr Other Mycobact Dis; 1973; 41(3):382-91. PubMed ID: 4130572
    [No Abstract]   [Full Text] [Related]  

  • 29. Maintenance of leprosy endemicity and bacterial positivity of lepromatous patients under treatment with sulfones.
    Bechelli LM; Dominguez VM
    Int J Lepr Other Mycobact Dis; 1971; 39(2):461. PubMed ID: 5169809
    [No Abstract]   [Full Text] [Related]  

  • 30. [In vitro immunologic changes in 4 patients with lepromatous leprosy treated for 1 year with rifampicin and sulfones and left untreated the following year].
    Saint-André P
    Acta Leprol; 1979; (76-77):301-2. PubMed ID: 121849
    [No Abstract]   [Full Text] [Related]  

  • 31. Prevalence of secondary dapsone resistance in Gudiyattam Taluk, the leprosy control area of the Schieffelin Leprosy Research and Training Centre, Karigiri. 1. Preliminary report.
    Balraj V; Jesudasan K; Chacko CJ; Christian M; Taylor PM; Fritschi EP; Job CK
    Int J Lepr Other Mycobact Dis; 1980 Dec; 48(4):397-401. PubMed ID: 7193654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A controlled trial to compare the therapeutic effects of dapsone in combination with daily or once-monthly rifampin in patients with lepromatous leprosy.
    Opromolla DV; Tonello CJ; McDougall AC; Yawalkar SJ
    Int J Lepr Other Mycobact Dis; 1981 Dec; 49(4):393-7. PubMed ID: 7042603
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of diaminodiphenylsulfone and thiosemicarbazone in the treatment of lepromatous leprosy; clinical and bacteriological evaluation in sixty hospitalized patients.
    SAGHER F; BRAND N
    Int J Lepr; 1953; 21(2):161-7. PubMed ID: 13096167
    [No Abstract]   [Full Text] [Related]  

  • 34. Repository acedapsone in leprosy chemoprophylaxis and treatment.
    Sloan NR; Worth RM; Jano B; Fasal P; Shepard CC
    Lancet; 1971 Sep; 2(7723):525-6. PubMed ID: 4105668
    [No Abstract]   [Full Text] [Related]  

  • 35. Malaria, leprosy and dapsone.
    Saha K; Kapoor L; Arora VM; Chattopadhya D
    Southeast Asian J Trop Med Public Health; 2003 Sep; 34(3):501-4. PubMed ID: 15115119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sural nerve biopsy in leprosy patients after varying periods of treatment: histopathological and bacteriological findings on light microscopy.
    Haimanot RT; Mshana RN; McDougall AC; Andersen JG
    Int J Lepr Other Mycobact Dis; 1984 Jun; 52(2):163-70. PubMed ID: 6539309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Studies on sulfone resistance in leprosy. I. Detection of cases.
    Pettit JH; Rees RJ; Ridley DS
    Int J Lepr Other Mycobact Dis; 1966; 34(4):375-90. PubMed ID: 6006069
    [No Abstract]   [Full Text] [Related]  

  • 38. Chemotherapeutic trials in leprosy. 3. Pilot trial of a riminophenazine derivative. B.663, in the treatment of lepromatous leprosy.
    Pettit JH; Rees RJ; Ridley DS
    Int J Lepr Other Mycobact Dis; 1967; 35(1):25-33. PubMed ID: 5336368
    [No Abstract]   [Full Text] [Related]  

  • 39. [101 cases of lepromatous leprosy under observation without treatment after stable negativation. Evaluation 20 years later].
    Mugnier P; Rollier M; Rollier R
    Acta Leprol; 1982; (86-87):185-8. PubMed ID: 6815987
    [No Abstract]   [Full Text] [Related]  

  • 40. The nose in lepromatous leprosy; bacteriological and histopathological studies of patients treated with dapsone monotherapy for varying periods of time.
    Barton RP; Rees RJ; McDougall AC; Ellard GA
    Int J Lepr Other Mycobact Dis; 1982 Mar; 50(1):58-67. PubMed ID: 7200473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.